Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City.

Company President and CEO Dror Bashan will deliver a presentation on Wednesday, September 11, at 12:30 p.m. EDT in the Holmes II Room on the Fourth floor. The management team will also engage in one-on-one meetings with registered investors throughout the conference.

Protalix is known for its proprietary ProCellEx® plant cell-based protein expression system, which is used in the development and production of recombinant therapeutic proteins.

News Market Reaction – PLX

-5.61%

1 alert

-5.61% News Effect

On the day this news was published, PLX declined 5.61%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CARMIEL, Israel, Sept. 4, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference which is being held on September 9–11, 2024 at the Lotte New York Palace Hotel, New York City, NY.

Mr. Bashan will present on Wednesday, September 11, at 12:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth floor. Management will participate in one-on-one meetings throughout the conference with registered investor attendees.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency (EMA) in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others.

Investor Contact

Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302237774.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When and where is Protalix BioTherapeutics (PLX) presenting at the H.C. Wainwright conference?

Protalix BioTherapeutics (PLX) is presenting on Wednesday, September 11, 2024, at 12:30 p.m. EDT in the Holmes II Room, Fourth floor of the Lotte New York Palace Hotel in New York City.

What is the date range for the H.C. Wainwright 26th Annual Global Investment Conference?

The H.C. Wainwright 26th Annual Global Investment Conference is being held from September 9-11, 2024.

Who will be representing Protalix BioTherapeutics (PLX) at the H.C. Wainwright conference?

Dror Bashan, the President and Chief Executive Officer of Protalix BioTherapeutics, will be presenting at the conference.

What type of meetings will Protalix BioTherapeutics (PLX) management participate in during the conference?

Protalix BioTherapeutics management will participate in one-on-one meetings with registered investor attendees throughout the conference.

What is Protalix BioTherapeutics' (PLX) main focus as a biopharmaceutical company?

Protalix BioTherapeutics focuses on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system.